BlackRock, Inc. Increases Stake in Ocular Therapeutix, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A, disclosing an increased ownership in Ocular Therapeutix, Inc. As of September 30, 2025, BlackRock, Inc. beneficially owns 10,170,232 shares of common stock, representing a 5.8% ownership stake. This marks a significant increase from previous filings, with the value of the holdings rising to $11,809,266,589.12, a 188.57% increase. The filing indicates that BlackRock, Inc. has sole voting power over 9,950,244 shares and sole dispositive power over all 10,170,232 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.